Composition for Prevention and Treatment of Contact Lens Papillary Conjunctivitis and Allergic Eye Disease

Abstract

The invention provides a use of panthenol or dexpanthenol in the prevention and / or treatment of contact lens papillary conjunctivitis in a subject. A contact lens care solution containing 0.001 to 10% by dry weight dexpanthenol is also provided.

Description

CROSS REFERENCE TO RELATED APPLICATION[0001]This application is a continuation of U.S. application Ser. No. 13 / 806,249, filed Dec. 21, 2012, which is the National Phase application of International Application No. PCT / AU2011 / 000827, filed Jul. 1, 2011, which designates the United States and was published in English. These applications, in their entirety, are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to pharmaceutical eye compositions comprising panthenol or dexpanthenol and their use for the prevention and / or treatment of contact lens papillary conjunctivitis, mechanical trauma and friction-induced eye disease and allergic eye disease. In a preferred embodiment, the eye disease is contact lens papillary conjunctivitis.BACKGROUND OF THE INVENTION[0003]Contact lens papillary conjunctivitis, also known as giant papillary conjunctivitis, occurs in contact lens wearers and is one of the major reasons that contact lens wearers discontinue l...

AI Technical Summary

Benefits of technology

The invention is about using dexpanthenol to treat or prevent eye conditions such as contact lens papillary conjunctivitis, mechanical trauma and friction-induced eye disease, and allergic eye disease. Dexpanthenol was found to reduce symptoms of these conditions when applied to the eye, particularly by reducing the occurrence of papillae on the upper tarsal conjunctiva and signs of redness. It can be used in higher quantities than other treatments without causing any harm and can be applied through a contact lens or directly to the eye. The invention also includes using dexpanthenol in a contact care solution or eye drops to administer it to the eye. Overall, the invention provides a safe and effective way to prevent and treat these eye conditions.

Problems solved by technology

The condition results in acute patient discomfort, intolerance to contact lens wear, itching, mucus discharge, excessive movement of the lens on the eye and deposits on the lens.

Often lens wearers are required to reduce the wearing time of lenses to reduce the frequency of symptoms but left unmanaged the condition ultimately leads to drop outs from lens wear.

Deposits on the lenses can also cause mechanical irritation.

In this condition papillae form on the upper tarsal conjunctiva of the upper eyelid, which cause discomfort due to the sensitive nature of the tissue.

The condition is characterised by itching of the eye and subjects may also complain of tearing, redness and burning.

Although the occurrence of subsequent instances of contact lens papillary conjunctivitis can be reduced by using daily lenses, this is not an ideal solution.

Existing methods of treatment of both contact lens papillary conjunctivitis and allergic eye disease using eye drops, for example the application of steroids, are hampered by the effect of the eye to quickly drain off tears.

There remains therefore a significant challenge in treating the above conditions safely, conveniently and cost-effectively.